D.R. Kaidarova ^1,2, A.Zh. Abdrakhmanova ^1,2, M.S. Dmitrenko ¹, A.B. Baizhigitov ¹, N.A. Chichua ¹, K.К. Smagulova ^1,2, R.Z. Abdrakhmanov ^1,2, S.N. Kaldarbekov ²

1. JSC «Kazakh Institute of Oncology and Radiology,» Almaty, the Republic of Kazakhstan;
2. NAO «Asfendiyarov Kazakh National Medical University,» Almaty, the Republic of Kazakhstan

DOI: https://www.doi.org/10.52532/2521-6414-2022-4-66-53-58

UDC: 618.19-006.6-055.1

Year: 2022 issure: 66 number: 4 pages: 53-58

Download PDF:

ABSTRACT

Relevance: Male breast cancer (BC) has always been behind female BC in detection, treatment, and surveillance. Lower BC frequency in men limits the usefulness of screening. However, BC incidence in men is growing.
This paper demonstrates the results of surgical treatment and typical changes in clinical and morphological manifestations of male breast cancer under chemotherapy and surgery.
Methods: The article describes a clinical case of a male patient diagnosed with “Cancer in the right breast St III (T4NxM0), edematousinfiltrative form with an intraductal component, upper outer localization. Immunohistochemically luminal subtype B without Her2neu expression”; the condition – after six neoadjuvant chemotherapy courses.
Results: Ultrasonography of the mammary glands conducted after six preoperative courses of chemotherapy showed a hypoechoic formation, centralized, with fuzzy, uneven contours, 52.5×48.2×46.1 mm in size, V=60.98 cm3. Compared to March 2022 (the presence of a formation in the right breast craniolateral quadrant, with precise uneven contours, 9.0 cm in size, with infiltrating growth), the tumor formation decreased to US BI-RADS R6, L2. The multidisciplinary council prescribed surgery to the extent of radical mastectomy by Madden on the right and simple mastectomy on the left. The surgery was performed in August 2022. According to a postoperative histological conclusion, the therapeutic pathomorphism was index RCB-2.233, class RCB-II.
Conclusion: This article shares the results of systemic and surgical treatment of a man with breast cancer. Considering the clinical picture and anamnesis, literature data, and the clinical protocol, the multidisciplinary group recommended radiation therapy with adjuvant endocrine therapy with tamoxifen for an initial period of five years.
Keywords: clinical case, male breast cancer (BC), luminal subtype B without Her2neu expression, mastectomy, therapeutic pathomorphism, radiation therapy, endocrine therapy.

* clinical case, male breast cancer (BC), luminal subtype B without Her2neu expression, mastectomy, therapeutic pathomorphism, radiation therapy, endocrine therapy.

List of sources used:

1. Cardoso F., Bartlett J. M. S., Slaets L., Van Deurzen C. H. M., Van Leeuwen-Stok E., Porter P., Linderholm B., Hedenfalk I., Schröder C., Martens J., Bayani J., van Asperen C., Murray M., Hudis C., Middleton L., Vermeij J., Punie K., Fraser J., Nowaczyk M., Rubio I.T., Aebi S., Kelly C., Ruddy K.J., Winer E., Nilsson C., Dal Lago L., Korde L., Benstead K., Bogler O., Goulioti T., Peric A., Litiere S., Aalders K.C., Poncet C., Tryfonidis K., Giordano S.H. Characterization of male breast cancer: results of the EORTC 10085 // TBCRC BIG NABCG International Male Breast Cancer Program Annals of Oncology. – 2018. – Vol. 29(2). – Р. 405-417. https://doi.org/10.1093/annonc/mdx651
2. Быкова А.В, Воротников И.К., Вишневская Я.В., Денчик Д.А., Любченко Л.Н. Проблема рака молочной железы у мужчин // Сиб. Онкол. Ж. – 2011. – №4. – С. 64-68 [Bykova A.V, Vorotnikov I.K., Vishnevskaya Ya.V., Denchik D.A., Lyubchenko L.N. Problema raka molochnoj zhelezy u muzhchin // Sib. Onkol. Zh. – 2011. – №4. – S. 64-68 (in Russ.)]. https://cyberleninka.ru/article/n/problema-raka-molochnoy-zhelezy-u-muzhchin
3. Brinton L.A., Carreon J.D., Gierach G.L., McGlynn K.A., Gridley G. Etiologic factors for male breast cancer in the US Veterans affairs’ medical care system database // Breast Cancer Res. Treat. – 2010. – Vol. 119. – P. 185-192. https://doi.org/10.1007/s10549-009-0379-0
4. Lin A.P., Huang T.W., Tam K.W. Treatment of male breast cancer: meta-analysis of real-world evidence // BJS. – 2021. – Vol. 108(9). – P. 1034-1042. https://doi.org/10.1093/bjs/znab279.
5. КайдароваД.Р., ДмитренкоМ.С., ЧичуаН.А., СмагуловаК.К., АбдрахмановР.З., КалдарбековС.Н., ҚалменП.Б.Клиническийслучайлеченияракамолочнойжелезыупациентамужскогопола // ОнкологияирадиологияКазахстана. – 2022. – №2(64). – С. 33-37 [KaidarovaD.R., DmitrenkoM.S., ChichuaN.A., SmagulovaK.К., AbdrakhmanovR.Z., KaldarbekovS.N., KalmenP.B. Klinicheskii sluchai lecheniya raka molochnoi zhelezy u pacienta muzhskogo pola // Onkologiya i radiologa Kazahstana. – 2022. – №2(64). – P. 33-37 (in Russ.)]. https://doi.org/10.52532/2521-6414-2022-2-64-33-38
6. Korde L.A., Zujewski J.A., Kamin L., Giordano S., Domchek S., Anderson W.F. Multidisciplinary meeting on male breast cancer: summary and research recommendations // J. Clin. Oncol. – 2010. – Vol. 28(12). – P. 2114-2122. https://ascopubs.org/doi/10.1200/JCO.2009.25.5729
7. Khan N. A. J., Tirona M. An updated review of epidemiology, risk factors, and management of male breast cancer // Med. Oncol. – 2019. – Vol. 38(4). – P. 136-138. https://doi.org/10.1007/s12032-021-01486-x
8. Munoz Carrasco R., Alvarez Benito M., Rivin del Campo E. Value of mammography and breast ultrasound in male patients with nipple discharge // Eur. J. Radiol. – 2013. – Vol. 82. – P. 478-484. https://www.ejradiology.com/action/showPdf?pii=S0720-048X%2812%2900530-X
9. Niell B.L., Lourenco A.P., Moy L., Baron P., Didwania A.D., Heller S.L., Holbrook A.I., Le-Petross H.T., Lewin A.A., Mehta T.S., Slanetz P.J. ACR Appropriateness Criteria evaluation of the symptomatic male breast // J. Am. Coll. Radiol. – 2018. – Vol 15(11). – P. 313-320. https://linkinghub.elsevier.com/retrieve/pii/S1546144018311591
10. Fentiman I. Male breast cancer: a review // Ecancer medical science. – 2009. Vol. 3 – P. 140. https://doi.org/10.3332%2Fecancer.2009.140
11. Massarweh S.A., Sledge G.W., Miller D.P., McCullough D., Petkov V.I., Shak S. Molecular Characterization and Mortality from Breast Cancer in Men // J. Clin. Oncol. – 2018. – Vol. 36(14). – P. 1396-1404. https://doi.org/10.1200/jco.2017.76.8861
12. Bevier M., Sundquist K., Hemminki K. Risk of breast cancer in families of multiple affected women and men // Breast Cancer Res. Treat. – 2012. – Vol. 132(2). – P. 723-728. https://doi.org/10.1007/s10549-011-1915-2
13. Gucalp A., Traina T.A., Eisner J.R., Parker J.S., Selitsky S.R., Park B.H., Elias A.D., Baskin-Bey E.S., Cardoso F. Male breast cancer: a disease distinct from female breast cancer // Breast Cancer Res. Treat. – 2019. – Vol. 173(1). – P. 37-48. https://doi.org/10.1007/s10549-018-4921-9.
14. Severson T.M., Zwart W. A review of estrogen receptor/androgen receptor genomics in male breast cancer // Endocr. Relat. Cancer. – 2017. – Vol. 24(3). – P. R27-R34. https://doi.org/10.1530/ERC-16-0225
15. ТюляндинС.А., ЖуковаЛ.Г., КоролеваИ.А., ПароконнаяА.А., СемиглазоваТ.Ю., СтенинаМ.Б., ФроловаМ.А. Практическиерекомендацииполекарственномулечениюракамолочнойжелезы // Злокачественныеопухоли. – 2021. – Т. 11, №3s2-1. – С. 119-157 [Tyulyandin S.A., Zhukova L.G., Koroleva I.A., Parakonnaya A.A., Semiglazova T.Yu., Stenina M.B., Frolova M.A. Prakticheskie rekomendacii po lekarstvennomu lecheniyu raka molochnoi zhelezy // Zlokachestvennye opuholi. – 2021. – Vol. 11, no.3s2. – S. 119-157 (in Russ.)]. https://doi.org/10.18027/2224-5057-2021-11-3s2-09
16. Darkeh M.H.S.E., Azavedo E. Male breast cancer clinical features, risk factors, and current diagnostic and therapeutic approaches // Int. J. Clin. Med. – 2014. – Vol. (5). – P. 1068-1086. http://www.scirp.org/journal/ijcm.